{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:39:25Z","timestamp":1789731565039,"version":"4.0.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81602226"],"award-info":[{"award-number":["81602226"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"China Postdoctoral Science Foundation Funded Project","award":["2016M590641"],"award-info":[{"award-number":["2016M590641"]}]},{"name":"Provincial Project of Medical and Technology Development Program of Shandong","award":["2014WS0091"],"award-info":[{"award-number":["2014WS0091"]}]},{"name":"Provincial Natural Science Foundation of Shandong","award":["ZR2015HQ002"],"award-info":[{"award-number":["ZR2015HQ002"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.biopha.2019.108924","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T16:19:14Z","timestamp":1557850754000},"page":"108924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes"],"prefix":"10.1016","volume":"115","author":[{"given":"Peng","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilian","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2019.108924_bib0005","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7314\/APJCP.2016.17.1.381","article-title":"Epidemiology, incidence and mortality of bladder cancer and their relationship with the development index in the world","volume":"17","author":"Mahdavifar","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"11","key":"10.1016\/j.biopha.2019.108924_bib0010","first-page":"502","article-title":"The updated incidences and mortalities of major cancers in China, 2011","volume":"34","author":"Chen","year":"2015","journal-title":"Chin. J. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2019.108924_bib0015","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.biopha.2019.108924_bib0020","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ncponc1159","article-title":"Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties","volume":"5","author":"Choueiri","year":"2008","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"10061","key":"10.1016\/j.biopha.2019.108924_bib0025","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biopha.2019.108924_bib0030","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.biopha.2019.108924_bib0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.biopha.2019.108924_bib0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2019.108924_bib0045","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.urology.2013.01.027","article-title":"Challenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist","volume":"81","author":"Hansel","year":"2013","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.biopha.2019.108924_bib0050","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/mc.22125","article-title":"PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors","volume":"54","author":"Duenas","year":"2015","journal-title":"Mol. Carcinog."},{"issue":"15","key":"10.1016\/j.biopha.2019.108924_bib0055","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","article-title":"PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors","volume":"66","author":"Lopez-Knowles","year":"2006","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.biopha.2019.108924_bib0060","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.humpath.2011.10.026","article-title":"Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer","volume":"43","author":"Juanpere","year":"2012","journal-title":"Hum. Pathol."},{"issue":"11","key":"10.1016\/j.biopha.2019.108924_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013821","article-title":"FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy","volume":"5","author":"Kompier","year":"2010","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.biopha.2019.108924_bib0070","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1158\/0008-5472.CAN-12-1329","article-title":"FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth","volume":"72","author":"Du","year":"2012","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2019.108924_bib0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/path.4017","article-title":"CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma","volume":"227","author":"Rebouissou","year":"2012","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2019.108924_bib0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/path.4176","article-title":"TSC1 involvement in bladder cancer: diverse effects and therapeutic implications","volume":"230","author":"Guo","year":"2013","journal-title":"J. Pathol."},{"issue":"5","key":"10.1016\/j.biopha.2019.108924_bib0085","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.urolonc.2014.02.003","article-title":"The role of PTEN tumor suppressor pathway staining in carcinoma in situ of the bladder","volume":"32","author":"Sfakianos","year":"2014","journal-title":"Urol. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2019.108924_bib0090","first-page":"4915","article-title":"TP53 and FGFR3 Gene mutation assessment in urine: pilot study for bladder Cancer diagnosis","volume":"35","author":"Noel","year":"2015","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2019.108924_bib0095","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1535-7163.MCT-14-0622-T","article-title":"Combined CDKN1A\/TP53 mutation in bladder cancer is a therapeutic target","volume":"14","author":"Liu","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"Pt 11","key":"10.1016\/j.biopha.2019.108924_bib0100","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1242\/jcs.00493","article-title":"An epigenetic road map for histone lysine methylation","volume":"116","author":"Lachner","year":"2003","journal-title":"J. Cell. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2019.108924_bib0105","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/ncb0503-395","article-title":"Chromatin and transcription: histones continue to make their marks","volume":"5","author":"Jaskelioff","year":"2003","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.biopha.2019.108924_bib0110","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2217\/epi.15.1","article-title":"Disrupted intricacy of histone H3K4 methylation in neurodevelopmental disorders","volume":"7","author":"Vallianatos","year":"2015","journal-title":"Epigenomics"},{"issue":"16","key":"10.1016\/j.biopha.2019.108924_bib0115","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1158\/0008-5472.CAN-16-0481","article-title":"Reduced expression of histone methyltransferases KMT2C and KMT2D correlates with improved outcome in pancreatic ductal adenocarcinoma","volume":"76","author":"Dawkins","year":"2016","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2019.108924_bib0120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cancergen.2015.01.005","article-title":"The cancer COMPASS: navigating the functions of MLL complexes in cancer","volume":"208","author":"Ford","year":"2015","journal-title":"Cancer Genet."},{"issue":"4","key":"10.1016\/j.biopha.2019.108924_bib0125","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.cell.2011.01.020","article-title":"Role for Dpy-30 in ES cell-fate specification by regulation of H3K4 methylation within bivalent domains","volume":"144","author":"Jiang","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2019.108924_bib0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1475-2867-10-13","article-title":"Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon","volume":"10","author":"Natarajan","year":"2010","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.biopha.2019.108924_bib0135","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4149\/neo_2013_025","article-title":"Mutational and expressional analysis of MLL genes in gastric and colorectal cancers with microsatellite instability","volume":"60","author":"Je","year":"2013","journal-title":"Neoplasma"},{"issue":"7406","key":"10.1016\/j.biopha.2019.108924_bib0140","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"issue":"7360","key":"10.1016\/j.biopha.2019.108924_bib0145","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.biopha.2019.108924_bib0150","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.biopha.2019.108924_bib0155","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat. Genet."},{"issue":"14","key":"10.1016\/j.biopha.2019.108924_bib0160","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41388-017-0099-6","article-title":"A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer","volume":"37","author":"Fantini","year":"2018","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.biopha.2019.108924_bib0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20040980","article-title":"Metallothionein 3 is a hypoxia-upregulated oncogene enhancing cell invasion and tumorigenesis in human bladder carcinoma cells","volume":"20","author":"Tsui","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2019.108924_bib0170","first-page":"1022","article-title":"LncSNHG14 promotes the development and progression of bladder cancer by targeting miRNA-150-5p","volume":"23","author":"Li","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2019.108924_bib0175","doi-asserted-by":"crossref","first-page":"e6207","DOI":"10.1590\/1414-431x20176207","article-title":"Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells","volume":"50","author":"Cao","year":"2017","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.biopha.2019.108924_bib0180","doi-asserted-by":"crossref","DOI":"10.1111\/bju.14370","article-title":"Germline mutations in DNA repair genes are associated with bladder cancer risk and unfavourable prognosis","author":"Na","year":"2018","journal-title":"BJU Int."},{"issue":"7216","key":"10.1016\/j.biopha.2019.108924_bib0185","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.biopha.2019.108924_bib0190","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/gtmb.2011.0227","article-title":"Detection of mitochondrial DNA mutations in nonmuscle invasive bladder cancer","volume":"16","author":"Guney","year":"2012","journal-title":"Genet. Test. Mol. Biomarkers"},{"issue":"3","key":"10.1016\/j.biopha.2019.108924_bib0195","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/cge.12484","article-title":"Immunologic assessment and KMT2D mutation detection in Kabuki syndrome","volume":"88","author":"Lin","year":"2015","journal-title":"Clin. Genet."},{"key":"10.1016\/j.biopha.2019.108924_bib0200","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddy241","article-title":"Dissecting KMT2D missense mutations in kabuki syndrome patients","author":"Cocciadiferro","year":"2018","journal-title":"Hum. Mol. Genet."},{"issue":"7484","key":"10.1016\/j.biopha.2019.108924_bib0205","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2019.108924_bib0210","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nrc3929","article-title":"Hijacked in cancer: the KMT2 (MLL) family of methyltransferases","volume":"15","author":"Rao","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2019.108924_bib0215","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.biopha.2019.108924_bib0220","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/gcc.22267","article-title":"Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene","volume":"54","author":"Juhlin","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"issue":"7498","key":"10.1016\/j.biopha.2019.108924_bib0225","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature13176","article-title":"Identification of genomic alterations in oesophageal squamous cell cancer","volume":"509","author":"Song","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2019.108924_bib0230","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1038\/ncomms8686","article-title":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","volume":"6","author":"Sausen","year":"2015","journal-title":"Nat. Commun."},{"issue":"7471","key":"10.1016\/j.biopha.2019.108924_bib0235","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2019.108924_bib0240","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/j.cllc.2018.03.005","article-title":"KMT2D mutation is associated with poor prognosis in non-small-Cell lung Cancer","volume":"19","author":"Ardeshir-Larijani","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2019.108924_bib0245","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00432-018-2625-5","article-title":"High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma","volume":"144","author":"Abudureheman","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2019.108924_bib0250","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41388-017-0026-x","article-title":"Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4","volume":"37","author":"Lv","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2019.108924_bib0255","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbrc.2018.08.143","article-title":"Downregulation of KMT2D suppresses proliferation and induces apoptosis of gastric cancer","volume":"504","author":"Xiong","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.biopha.2019.108924_bib0260","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3943","article-title":"The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development","volume":"21","author":"Ortega-Molina","year":"2015","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.biopha.2019.108924_bib0265","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/nm.3940","article-title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.biopha.2019.108924_bib0270","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","article-title":"FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease","volume":"25","author":"Jen","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2019.108924_bib0275","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3892\/ijo.2014.2568","article-title":"Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax","volume":"45","author":"Jiao","year":"2014","journal-title":"Int. J. Oncol."},{"issue":"Suppl.10","key":"10.1016\/j.biopha.2019.108924_bib0280","first-page":"240","article-title":"Recent advances of histone modification in gastric cancer","author":"Yang","year":"2014","journal-title":"J. Cancer Res. Ther."},{"issue":"7143","key":"10.1016\/j.biopha.2019.108924_bib0285","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature05915","article-title":"The complex language of chromatin regulation during transcription","volume":"447","author":"Berger","year":"2007","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.biopha.2019.108924_bib0290","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.18632\/oncotarget.1555","article-title":"KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation","volume":"4","author":"Guo","year":"2013","journal-title":"Oncotarget"},{"issue":"42","key":"10.1016\/j.biopha.2019.108924_bib0295","doi-asserted-by":"crossref","first-page":"11871","DOI":"10.1073\/pnas.1606857113","article-title":"Enhancer priming by H3K4 methyltransferase MLL4 controls cell fate transition","volume":"113","author":"Wang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"23","key":"10.1016\/j.biopha.2019.108924_bib0300","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1128\/MCB.01181-13","article-title":"The MLL3\/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers","volume":"33","author":"Hu","year":"2013","journal-title":"Mol. Cell. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2019.108924_bib0305","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cub.2010.01.017","article-title":"Methylation of H3K4 is required for inheritance of active transcriptional states","volume":"20","author":"Muramoto","year":"2010","journal-title":"Curr. Biol."},{"issue":"51","key":"10.1016\/j.biopha.2019.108924_bib0310","doi-asserted-by":"crossref","first-page":"49383","DOI":"10.1074\/jbc.M209294200","article-title":"Association of the histone methyltransferase Set2 with RNA polymerase II plays a role in transcription elongation","volume":"277","author":"Li","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2019.108924_bib0315","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.bulcan.2018.07.015","article-title":"Precision medicine and bladder cancer heterogeneity","volume":"105","author":"Ma","year":"2018","journal-title":"Bull. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2019.108924_bib0320","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.molcel.2018.04.028","article-title":"MLL4 is required to maintain broad H3K4me3 peaks and super-enhancers at tumor suppressor genes","volume":"70","author":"Dhar","year":"2018","journal-title":"Mol. Cell"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218384117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218384117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:43:07Z","timestamp":1760096587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218384117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":64,"alternative-id":["S0753332218384117"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2019.108924","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2019.108924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"108924"}}